JP5992049B2 - 置換されたキナゾリノンのための経口速放性製剤 - Google Patents

置換されたキナゾリノンのための経口速放性製剤 Download PDF

Info

Publication number
JP5992049B2
JP5992049B2 JP2014537747A JP2014537747A JP5992049B2 JP 5992049 B2 JP5992049 B2 JP 5992049B2 JP 2014537747 A JP2014537747 A JP 2014537747A JP 2014537747 A JP2014537747 A JP 2014537747A JP 5992049 B2 JP5992049 B2 JP 5992049B2
Authority
JP
Japan
Prior art keywords
hydroxyethoxy
active ingredient
dimethoxyquinazolin
dimethylphenyl
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014537747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014532638A (ja
JP2014532638A5 (enExample
Inventor
ナーマダ・アール・シェノイ
Original Assignee
レスバーロジックス コーポレイション
レスバーロジックス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レスバーロジックス コーポレイション, レスバーロジックス コーポレイション filed Critical レスバーロジックス コーポレイション
Publication of JP2014532638A publication Critical patent/JP2014532638A/ja
Publication of JP2014532638A5 publication Critical patent/JP2014532638A5/ja
Application granted granted Critical
Publication of JP5992049B2 publication Critical patent/JP5992049B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2014537747A 2011-11-01 2012-10-31 置換されたキナゾリノンのための経口速放性製剤 Active JP5992049B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161554090P 2011-11-01 2011-11-01
US61/554,090 2011-11-01
PCT/IB2012/002721 WO2013064900A1 (en) 2011-11-01 2012-10-31 Oral immediate release formulations for substituted quinazolinones

Publications (3)

Publication Number Publication Date
JP2014532638A JP2014532638A (ja) 2014-12-08
JP2014532638A5 JP2014532638A5 (enExample) 2015-12-17
JP5992049B2 true JP5992049B2 (ja) 2016-09-14

Family

ID=48172690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014537747A Active JP5992049B2 (ja) 2011-11-01 2012-10-31 置換されたキナゾリノンのための経口速放性製剤

Country Status (22)

Country Link
US (2) US9610251B2 (enExample)
EP (1) EP2773354B1 (enExample)
JP (1) JP5992049B2 (enExample)
KR (1) KR102011641B1 (enExample)
CN (1) CN103945848B (enExample)
AU (1) AU2012330885B2 (enExample)
CA (1) CA2851996C (enExample)
CY (1) CY1123945T1 (enExample)
DK (1) DK2773354T3 (enExample)
ES (1) ES2745471T3 (enExample)
HR (1) HRP20191587T1 (enExample)
HU (1) HUE044986T2 (enExample)
IL (1) IL232041B (enExample)
IN (1) IN2014CN02751A (enExample)
LT (1) LT2773354T (enExample)
PL (1) PL2773354T3 (enExample)
PT (1) PT2773354T (enExample)
RS (1) RS58911B1 (enExample)
RU (1) RU2640115C2 (enExample)
SI (1) SI2773354T1 (enExample)
TR (1) TR201909777T4 (enExample)
WO (1) WO2013064900A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11015868B2 (en) * 2017-04-25 2021-05-25 Emil Jacob Gulbranson Hay bale dryer

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX364444B (es) 2006-06-07 2019-04-26 Genzyme Corp Terapia génica para esclerosis lateral amiotrófica y otros trastornos de la médula espinal.
EP3632472A1 (en) 2006-10-03 2020-04-08 Genzyme Corporation Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
SI2118074T1 (sl) 2007-02-01 2014-05-30 Resverlogix Corp. Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni
NZ594332A (en) 2009-01-08 2013-09-27 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular disease
CN105859639A (zh) 2009-03-18 2016-08-17 雷斯韦洛吉克斯公司 新的抗炎剂
BRPI1014956B8 (pt) 2009-04-22 2021-05-25 Resverlogix Corp agentes anti-inflamatórios
AU2012330885B2 (en) 2011-11-01 2016-10-06 Resverlogix Corp. Oral immediate release formulations for substituted quinazolinones
DK2906531T3 (en) 2012-10-15 2018-02-05 Resverlogix Corp APPLICABLE COMPOUNDS IN THE SYNTHESIS OF BENZAMIDE COMPOUNDS
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
CA2895905A1 (en) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Novel heterocyclic compounds as bromodomain inhibitors
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
US20160095867A1 (en) * 2013-05-28 2016-04-07 Dana-Farber Cancer Institute, Inc. Bet inhibition therapy for heart disease
WO2015004533A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
PL3010503T3 (pl) 2013-06-21 2020-08-24 Zenith Epigenetics Ltd. Nowe bicykliczne inhibitory bromodomen
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
EP3027604B1 (en) * 2013-07-31 2019-02-20 Zenith Epigenetics Ltd. Novel quinazolinones as bromodomain inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
KR102702503B1 (ko) 2014-04-23 2024-09-05 인사이트 홀딩스 코포레이션 BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
WO2016044130A1 (en) 2014-09-15 2016-03-24 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
KR20170055549A (ko) * 2014-10-02 2017-05-19 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 화합물
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
EP3227280B1 (en) 2014-12-01 2019-04-24 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
CN107207474B (zh) 2014-12-11 2021-05-07 恒翼生物医药科技(上海)有限公司 被取代的杂环作为溴结构域抑制剂
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
JO3789B1 (ar) 2015-03-13 2021-01-31 Resverlogix Corp التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
PH12021551886A1 (en) 2016-06-20 2023-07-17 Incyte Corp Crystalline solid forms of a bet inhibitor
EP3558950B1 (en) * 2016-12-20 2023-05-10 Oligomerix, Inc. Novel quinazolinones that inhibit the formation of tau oligomers and their method of use
WO2018118782A2 (en) 2016-12-20 2018-06-28 Oligomerix, Inc. Novel benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use
CN108484510B (zh) * 2018-05-18 2020-05-05 东南大学 一种基于brd4抑制剂rvx-208的衍生物及其制备方法和应用
WO2021107657A1 (ko) * 2019-11-26 2021-06-03 주식회사 베노바이오 신규한 퀴나졸린 리독스 유도체 및 bet 억제제로서의 용도
WO2021107656A2 (ko) * 2019-11-26 2021-06-03 주식회사 베노바이오 신규한 퀘르세틴 리독스 유도체 및 bet 억제제로서의 용도
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
TW202233195A (zh) * 2020-10-30 2022-09-01 加拿大商瑞斯弗洛吉克斯公司 以BET溴結構域抑制劑及鈉依賴型葡萄糖轉運2抑制劑之組合於降低HbA1c含量之方法

Family Cites Families (235)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2065593A (en) 1936-12-29 Water-soluble diazoimino com
FR472489A (fr) 1914-02-20 1914-12-08 Stas Motor Ges M B H Bague de garniture métallique pour pistons
US2065900A (en) 1935-03-23 1936-12-29 Gen Aniline Works Inc Dihydroxystilbene-dicarboxylic acid and a process of preparing it
US2071329A (en) 1935-08-22 1937-02-23 Solvay Process Co Method of recovering phthalic anhydride
GB728767A (en) 1951-10-12 1955-04-27 Wander Ag Dr A 2-substituted chromone compounds, and a method of making same
GB726767A (en) 1952-12-19 1955-03-23 Kodak Ltd Improvements in or relating to a web perforator
US3251837A (en) 1962-09-14 1966-05-17 Pfizer & Co C Derivatives of 1, 2, 4-benzothiadiazine-1, 1-dioxides
GB1179019A (en) 1967-05-23 1970-01-28 Produits Chimique Soc Et Polynicotinic Esters of Flavonoids
FR6928M (enExample) 1967-11-24 1969-05-05
US3600394A (en) 1968-05-17 1971-08-17 Searle & Co 2-aminoalkyl-3-arylisocarbostyrils
US3773946A (en) 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
US3930024A (en) 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
FR2244493A1 (en) 1973-08-09 1975-04-18 Pluripharm Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis
DE2349024A1 (de) 1973-09-26 1975-04-10 Schering Ag 6beta,7beta-epoxy-1alpha,2alphamethylen-d-homo-4-pregnen-3,20-dione
US5098903A (en) 1980-03-07 1992-03-24 Board Of Regents Of The University Of Oklahoma Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents
IL64542A0 (en) 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
JPS60136512A (ja) 1983-12-26 1985-07-20 Eisai Co Ltd 脂質代謝改善剤
DE3423166A1 (de) 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
DE3579888D1 (de) 1984-11-08 1990-10-31 Sumitomo Pharma Carbapenemverbindungen und deren herstellung.
DE3515882A1 (de) 1985-05-03 1986-11-06 Dr. Karl Thomae Gmbh, 7950 Biberach Arzneimittel, enthaltend pyridinone mit antithrombotischen wirkungen und verfahren zu ihrer herstellung
DE3532279A1 (de) 1985-09-11 1987-03-12 Bayer Ag 1,4-benzoxathiin-derivate
DE3601417A1 (de) 1986-01-20 1987-07-23 Nattermann A & Cie 2'-alkyl-(alkenyl-) substituierte quercetine
US4825005A (en) 1986-08-29 1989-04-25 Ciba-Geigy Corporation Process for the preparation of aromatic ether and thioether compounds
ES2053508T3 (es) 1986-11-24 1994-08-01 Fujisawa Pharmaceutical Co Compuestos de acidos 3-pirrolidinil-tio-1-azabiciclo(3.2.0)hept-2-eno-2-carboxilicos.
GB8804058D0 (en) 1988-02-22 1988-03-23 Fujisawa Pharmaceutical Co 3-alkenyl-1-azabicyclo(3 2 0)hept-2-ene-2-carboxylic acid compounds
US4925838A (en) 1988-03-18 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. 3-pyrrolidinylthio-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid compounds
US4963544A (en) 1988-05-23 1990-10-16 Fujisawa Pharmaceutical Company, Ltd. 3-pyrrolidinylthio-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid compounds
GB8926981D0 (en) 1988-12-23 1990-01-17 Ici Plc Heterocyclic derivatives
KR920701167A (ko) 1989-07-07 1992-08-11 에릭 에스. 딕커 약제학적 활성 화합물
FR2649612A1 (fr) 1989-07-17 1991-01-18 Rhone Poulenc Sante Medicaments a base de derives de 1h-benzoxadiazine-4,1,2 nouveaux derives et leurs procedes de preparation
IE64358B1 (en) 1989-07-18 1995-07-26 Ici Plc Diaryl ether heterocycles
GB9018134D0 (en) 1989-09-29 1990-10-03 Ici Plc Heterocyclic derivatives
DE69125099T2 (de) 1990-06-05 1997-06-19 Toray Industries, Inc., Tokio/Tokyo Indolderivate
JP2999579B2 (ja) 1990-07-18 2000-01-17 武田薬品工業株式会社 Ｄｎａおよびその用途
GB9025832D0 (en) 1990-11-28 1991-01-09 Ashwell Geoffrey J Novel films for nonlinear optical applications
IE913866A1 (en) 1990-11-28 1992-06-03 Ici Plc Aryl derivatives
US5126351A (en) 1991-01-24 1992-06-30 Glaxo Inc. Antitumor compounds
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
JPH06504791A (ja) 1991-04-10 1994-06-02 オクタマー，インコーポレイティド レトロウィルス複製の阻害のための方法
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ES2108120T3 (es) 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
US5124337A (en) 1991-05-20 1992-06-23 Schering Corporation N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase
US5223506A (en) 1991-06-04 1993-06-29 Glaxo Inc. Cyclic antitumor compounds
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US5250679A (en) 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US5474994A (en) 1992-05-26 1995-12-12 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A
FR2689127B1 (fr) 1992-03-31 1994-05-06 Adir Cie Nouvelles 3', 5' -ditertbutyl-4'-hydroxy flavones, leur procede de preparation et les compositions pharmaceutiques les renfermant.
DE4215588A1 (de) 1992-05-12 1993-11-18 Bayer Ag Biphenylmethyl-substituierte Pyridone
DE4215587A1 (de) 1992-05-12 1993-11-18 Bayer Ag Sulfonylbenzyl-substituierte Benzo- und Pyridopyridone
GB9218334D0 (en) 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
JPH0680656A (ja) 1992-09-03 1994-03-22 Mitsui Petrochem Ind Ltd 光学活性エポキシドの製造方法
AU5850894A (en) 1992-12-23 1994-07-19 Procept, Inc. Novel agents for inhibition of hiv infectivity and use therefor
JPH0741442A (ja) 1993-05-21 1995-02-10 Sumitomo Chem Co Ltd アセチレンアルコール誘導体およびその製造法
JPH0761942A (ja) 1993-06-17 1995-03-07 Sumitomo Chem Co Ltd フェノール誘導体およびその製造法
JPH0725761A (ja) 1993-07-09 1995-01-27 Kureha Chem Ind Co Ltd 軟骨保護剤
WO1995003277A1 (en) 1993-07-23 1995-02-02 Zaidan Hojin Biseibutsu Kagaku Kenkyukai Novel pyrrolidine derivative
US5707547A (en) 1993-08-03 1998-01-13 Sumitomo Chemical Company, Limited Trans-olefin compounds, method for production thereof, liquid crystal composition containing the same as active ingredient, and liquid crystal element using said composition
JPH07118241A (ja) 1993-09-01 1995-05-09 Sumitomo Chem Co Ltd フェノール誘導体およびその製造法
JPH07179380A (ja) 1993-12-22 1995-07-18 Sumitomo Chem Co Ltd アルコール誘導体およびその製造法
JPH07233109A (ja) 1994-02-24 1995-09-05 Sumitomo Chem Co Ltd 光学活性なアルコール誘導体およびその製造法
US5707987A (en) 1994-02-25 1998-01-13 Banyu Pharmaceutical Co., Ltd. Carbapenem derivatives
KR100233703B1 (ko) 1994-03-08 1999-12-01 오츠까 요시미쯔 포스폰산 디에스테르 유도체
JPH07247289A (ja) 1994-03-11 1995-09-26 Mitsui Petrochem Ind Ltd クロメンオキシド類の製造方法
FR2718329B1 (fr) 1994-03-21 2002-09-20 Rhone Poulenc Rorer Sa Lapin transgénique sensibilisé aux dyslipoprotéinémies.
US6048903A (en) 1994-05-03 2000-04-11 Robert Toppo Treatment for blood cholesterol with trans-resveratrol
IL109633A (en) 1994-05-11 2005-05-17 Yeda Res & Dev Tnf receptor promoter
US6168776B1 (en) 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
GB2292149A (en) 1994-08-09 1996-02-14 Ferring Res Ltd Peptide inhibitors of pro-interleukin-1beta converting enzyme
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
ES2146782T3 (es) 1994-11-14 2000-08-16 Warner Lambert Co 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa.
US5446071A (en) 1994-11-18 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
JP4140981B2 (ja) 1994-12-26 2008-08-27 東菱薬品工業株式会社 再狭窄症及び動脈硬化症治療薬
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
AU5259296A (en) 1995-04-07 1996-10-23 Warner-Lambert Company Flavones and coumarins as agents for the treatment of athero sclerosis
ES2180702T3 (es) 1995-06-07 2003-02-16 Lilly Co Eli Tratamiento de patologias por la induccion del factor de transcripcion bef-1.
WO1997008153A1 (en) 1995-08-30 1997-03-06 Otsuka Pharmaceutical Factory, Inc. Process for producing quinazolin-4-one derivatives
AU4858596A (en) 1995-09-15 1997-04-01 Torrey Pines Institute For Molecular Studies Synthesis of quinazolinone libraries
US5783577A (en) 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
PL327617A1 (en) 1995-10-23 1998-12-21 Zymogenetics Inc Compositions for and methods of treating osseous insufficiency
RU2135494C1 (ru) 1995-12-01 1999-08-27 Санкио Компани Лимитед Гетероциклические соединения и композиция на их основе, проявляющая антагонистическое действие в отношении рецепторов тахикинина
US5756736A (en) 1996-01-26 1998-05-26 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US5763608A (en) 1996-02-05 1998-06-09 Hoechst Celanese Corporation Process for preparing pyrimidine derivatives
US5739330A (en) 1996-02-05 1998-04-14 Hoechst Celanese Corporation Process for preparing quinazolones
WO1997028118A1 (en) 1996-02-05 1997-08-07 Hoechst Celanese Corporation Process for preparing anthranilic acids
HUP9900413A3 (en) 1996-02-12 2002-02-28 Univ Rutgers Use of coralyne derivatives, new coralyne derivatives and use thereof, pharmaceutical compositions containing these new coralyne derivatives
KR20000022040A (ko) 1996-06-20 2000-04-25 보오드 오브 리젠츠, 더 유니버시티 오브 텍사스 시스템 약학적 활성 제제를 제공하기 위한 화합물, 방법 및 그의 용도
US5854264A (en) 1996-07-24 1998-12-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
KR100213895B1 (ko) 1996-10-14 1999-08-02 박원훈 감귤류 과피 추출물, 이로부터 분리 정제된 헤스페리딘 또는 나린진을 포함하는 심혈관 질환 예방및 치료제 조성물
DE19651099A1 (de) 1996-12-09 1998-06-10 Consortium Elektrochem Ind Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung
IL119971A (en) 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
JPH10287678A (ja) 1997-04-11 1998-10-27 Kyowa Hakko Kogyo Co Ltd ピラノアジン誘導体
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US5908861A (en) 1997-05-13 1999-06-01 Octamer, Inc. Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
JP4362638B2 (ja) 1997-05-13 2009-11-11 オクテイマー・インコーポレイテッド ｐＡＤＰＲＴインヒビターを用いる炎症および炎症性疾患の処置法
ATE222104T1 (de) 1997-06-02 2002-08-15 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen
IL121165A0 (en) 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
GB9716812D0 (en) 1997-08-09 1997-10-15 Process Intelligence Limited Memory test equipment with optimisation function
CN1159302C (zh) 1997-08-29 2004-07-28 武田舍林-普劳动物保健株式会社 三嗪衍生物,其制备及应用
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6239114B1 (en) 1997-09-26 2001-05-29 Kgk Synergize Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
WO1999018077A1 (en) 1997-10-02 1999-04-15 Eisai Co., Ltd. Fused pyridine derivatives
WO1999021548A1 (en) 1997-10-28 1999-05-06 Korea Institute Of Science And Technology Naringin and naringenin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor of macrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
DE19756388A1 (de) 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh Substituierte 2-Aryl-4-amino-chinazoline
DK1049767T3 (da) 1998-01-08 2005-09-19 Aventis Pharma Inc En transgen kanin, der udtrykker et funktionelt humant lipoprotein(A)
US6414037B1 (en) 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
US6022901A (en) 1998-05-13 2000-02-08 Pharmascience Inc. Administration of resveratrol to prevent or treat restenosis following coronary intervention
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
AU5759899A (en) 1998-09-24 2000-04-10 Mitsubishi Chemical Corporation Hydroxyflavone derivatives as tau protein kinase 1 inhibitors
CN1148188C (zh) 1998-10-19 2004-05-05 卫材株式会社 镇痛剂
CN1327384A (zh) 1998-10-20 2001-12-19 韩国科学技术研究院 作为血浆高密度脂蛋白浓度增高剂的生物类黄酮
US6433187B1 (en) 1998-12-17 2002-08-13 Tularik Inc. Certain polycyclic compounds useful as tubulin-binding agents
US6291456B1 (en) 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
HUP0201067A3 (en) 1999-03-15 2004-07-28 Abbott Lab 6-o-substituted macrolides having antibacterial activity, pharmaceutical compositions containing them, their use and process for preparation of the compounds
US6969720B2 (en) 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
US6054435A (en) 1999-03-19 2000-04-25 Abbott Laboratories 6-O-substituted macrolides having antibacterial activity
GB9909325D0 (en) 1999-04-22 1999-06-16 Gillette Co Pen nib
RU2267484C2 (ru) 1999-04-28 2006-01-10 Авентис Фарма Дойчланд Гмбх Производные диариловой кислоты и фармацевтическая композиция на их основе
US6835755B1 (en) 1999-06-24 2004-12-28 University Of Pretoria Naphthoquinone derivatives and their use in the treatment and control of tuberculosis
DE19934799B4 (de) 1999-07-28 2008-01-24 Az Electronic Materials (Germany) Gmbh Chiral-smektische Flüssigkristallmischung und ihre Verwendung in Aktivmatrix-Displays mit hohen Kontrastwerten
JP2001131151A (ja) 1999-11-02 2001-05-15 Shionogi & Co Ltd オレフィン誘導体の新規用途
JP5278983B2 (ja) 1999-11-17 2013-09-04 塩野義製薬株式会社 アミド化合物の新規用途
ES2334635T3 (es) 1999-12-06 2010-03-15 Welichem Biotech Inc. Polihidroxiestilbeno y oxidos de estilbeno como agentes antipsoriasicos e inhibidores de la proteina quinasa.
FR2804679B1 (fr) 2000-02-07 2002-04-26 Clariant France Sa Nouveaux composes phenoliques derives des dialcoxyethanals, leur procede de preparation et leur application
JP2003522810A (ja) 2000-02-17 2003-07-29 アップルトン ペーパーズ インコーポレイテッド アルコキシ又はアリルメトキシエタンの製造方法
WO2001083456A1 (en) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
AU6118001A (en) 2000-05-03 2001-11-12 Tularik Inc Combination therapeutic compositions and methods of use
US6548694B2 (en) 2000-05-23 2003-04-15 Hoffman-La Roche Inc. N-(4-carbamimidoyl-phenyl)-glycine derivatives
JP2001335476A (ja) 2000-05-29 2001-12-04 Shionogi & Co Ltd 三環化合物の新規用途
US6479499B1 (en) 2000-06-28 2002-11-12 National Science Council 2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions
JP2002047283A (ja) 2000-07-04 2002-02-12 Basf Ag 新規フラボノイドおよびそれらの化粧用または皮膚科用製品における使用
US6541522B2 (en) 2000-08-16 2003-04-01 Insmed Incorporated Methods of using compositions containing hypotriglyceridemically active stilbenoids
CA2356544C (en) 2000-10-03 2006-04-04 Warner-Lambert Company Pyridotriazines and pyridopyridazines
CN1478077A (zh) 2000-10-05 2004-02-25 ����ҩƷ��ҵ��ʽ���� 作为apo b分泌抑制剂的苯甲酰胺化合物
CA2425678A1 (en) 2000-10-11 2002-04-18 Jean-Louis H. Dasseux Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
MXPA03003022A (es) 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de sulfuro y disulfuro y composiciones para el control del colesterol y usos relacionados.
AU3238102A (en) 2000-10-19 2002-04-29 Merck & Co Inc Estrogen receptor modulators
KR100846526B1 (ko) 2000-11-30 2008-07-15 캐논 가부시끼가이샤 발광 소자 및 표시 장치
US6593612B2 (en) 2000-12-05 2003-07-15 Infineon Technologies Ag Structure and method for forming a body contact for vertical transistor cells
CA2430951A1 (en) 2000-12-07 2002-06-13 Cv Therapeutics, Inc. Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
KR100472694B1 (ko) 2000-12-30 2005-03-07 한국생명공학연구원 플라바논 유도체 및 이를 포함하는 혈중 지질 농도 관련질환의 예방 및 치료용 조성물
JP2002249483A (ja) 2001-02-21 2002-09-06 Koei Chem Co Ltd アリール置換複素環式化合物の製造法
JP4786040B2 (ja) 2001-02-23 2011-10-05 独立行政法人科学技術振興機構 キラル補助基を効率的に除去する光学活性化合物の製造方法
WO2002074307A1 (en) 2001-03-16 2002-09-26 Novogen Research Pty Ltd Treatment of restenosis
EP1385501A2 (en) 2001-04-11 2004-02-04 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
JP2004535411A (ja) 2001-05-25 2004-11-25 ブリストルーマイヤーズ スクイブ カンパニー マトリックスメタロプロテナーゼ及び／またはＴＮＦ−α転換酵素（ＴＡＣＥ）の阻害剤としてのヒダントイン及び関連複素環化合物
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
US7173128B2 (en) 2001-08-13 2007-02-06 Ciba Specialty Chemicals Corporation Ultraviolet light absorbers
US20040248950A1 (en) 2001-08-24 2004-12-09 Natsuki Ishizuka Apo ai expression accelerating agent
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
EP2168576A3 (en) 2001-09-14 2010-05-26 Shionogi & Co., Ltd. Tricyclic compounds for treating dyslipidemia and arteriosclerotic diseases
US6835469B2 (en) 2001-10-17 2004-12-28 The University Of Southern California Phosphorescent compounds and devices comprising the same
US7166368B2 (en) 2001-11-07 2007-01-23 E. I. Du Pont De Nemours And Company Electroluminescent platinum compounds and devices made with such compounds
US7250512B2 (en) 2001-11-07 2007-07-31 E. I. Du Pont De Nemours And Company Electroluminescent iridium compounds having red-orange or red emission and devices made with such compounds
US6541045B1 (en) 2002-01-04 2003-04-01 Nutraceutical Corporation Herbal composition and method for combating inflammation
JP4389204B2 (ja) 2002-01-28 2009-12-24 宇部興産株式会社 キナゾリン−４−オン誘導体の製造方法
MXPA04008680A (es) 2002-02-19 2004-12-06 Pharmacia Italia Spa Derivados de pirazol triciclicos, procedimientos para su preparacion y su uso como agentes anti-tumorales.
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
TW200401770A (en) 2002-06-18 2004-02-01 Sankyo Co Fused-ring pyrimidin-4(3H)-one derivatives, processes for the preparation and uses thereof
KR20040001144A (ko) 2002-06-27 2004-01-07 김대경 신규한 적혈구 세포질형 포스포리파아제 에이 투 효소,그에 대한 항체, 이들의 용도 및 제조 방법
US20050080024A1 (en) 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
US20040033480A1 (en) 2002-08-15 2004-02-19 Wong Norman C.W. Use of resveratrol to regulate expression of apolipoprotein A1
US20050080021A1 (en) 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
CA2495903A1 (en) 2002-08-23 2004-03-04 University Of Connecticut Novel biphenyl and biphenyl-like cannabinoids
AU2003262946A1 (en) 2002-08-30 2004-03-19 Pharmacia And Upjohn Company Method of preventing or treating atherosclerosis or restenosis
EP1407774A1 (en) 2002-09-10 2004-04-14 LION Bioscience AG 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
EP1398032A1 (en) 2002-09-10 2004-03-17 PheneX Pharmaceuticals AG 4-Oxo-quinazolines as LXR nuclear receptor binding compounds
AU2003284001A1 (en) 2002-10-07 2004-05-04 Bristol-Myers Squibb Company Triazolone and triazolethione derivatives
AU2003301662A1 (en) 2002-10-21 2004-05-13 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
WO2004039795A2 (en) 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
EP1418164A1 (en) 2002-11-07 2004-05-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists
DE60327097D1 (de) 2002-11-18 2009-05-20 Hoffmann La Roche Diazinopyrimidine und ihre verwendung als proteinkinaseinhibitoren
RU2342388C2 (ru) 2002-11-22 2008-12-27 Джапан Тобакко Инк. Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием
ES2270154T3 (es) 2002-12-13 2007-04-01 F. Hoffmann-La Roche Ag Derivados de 3h-quinazolin-4-ona.
ITRM20020629A1 (it) 2002-12-19 2004-06-20 Sigma Tau Ind Farmaceuti Uso di acidi alfa-feniltiocarbossilici e alfa-fenilossicarbossilici ad attivita' ipoglicemizzante e/o ipolipidemizzante.
ES2361924T3 (es) 2002-12-20 2011-06-24 X-Ceptor Therapeutics, Inc. Derivados de isoquinolinona y su uso como agentes terapéuticos.
JP2004203751A (ja) 2002-12-24 2004-07-22 Pfizer Inc 置換６，６−ヘテロ二環式誘導体
AU2003292625B2 (en) 2002-12-26 2008-07-24 Eisai R & D Management Co., Ltd. Selective estrogen receptor modulators
WO2004065392A1 (en) 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
WO2004072042A2 (en) 2003-02-12 2004-08-26 Carex S.A. Quinoline derivative and their use for modulation of lxr activity
WO2004092154A1 (en) 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US7763627B2 (en) 2003-04-09 2010-07-27 Exelixis, Inc. Tie-2 modulators and methods of use
JP2004307440A (ja) 2003-04-10 2004-11-04 Kyorin Pharmaceut Co Ltd ２−アミノ‐１，３‐プロパンジオール誘導体とその付加塩
ATE422895T1 (de) 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
CA2525383C (en) 2003-06-06 2012-03-06 Arexis Ab Use of heterocyclic compounds as scce inhibitors
WO2004112710A2 (en) 2003-06-17 2004-12-29 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß
EP1637523A4 (en) 2003-06-18 2009-01-07 Ube Industries PROCESS FOR PRODUCING A PYRIMIDIN-4-ONE COMPOUND
US20050043300A1 (en) 2003-08-14 2005-02-24 Pfizer Inc. Piperazine derivatives
MXPA06003838A (es) 2003-10-10 2006-07-03 Resverlogix Corp Tratamiento de enfermedades asociadas con el elemento mejorador de egr-1.
WO2005042712A2 (en) 2003-10-28 2005-05-12 Reddy Us Therapeutics, Inc. Heterocyclic compounds and methods of making and using thereof
CA2549641A1 (en) 2003-12-19 2005-07-21 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2005066162A1 (en) 2003-12-23 2005-07-21 Human Biomolecular Research Institute Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer
US20050167025A1 (en) 2004-01-06 2005-08-04 Toshikazu Kobayashi Process for laser welding polyester compositions
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
JPWO2005115993A1 (ja) 2004-05-31 2008-03-27 萬有製薬株式会社 キナゾリン誘導体
WO2006012577A2 (en) 2004-07-22 2006-02-02 Bayer Pharmaceuticals Corporation Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake
US20070218155A1 (en) 2004-08-20 2007-09-20 Kuhrts Eric H Methods and compositions for treating dyslipidaemia
CA2584485C (en) 2004-10-20 2013-12-31 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
WO2006071095A1 (en) 2004-12-31 2006-07-06 Sk Chemicals Co., Ltd. Quinazoline derivatives for the treatment and prevention of diabetes and obesity
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
EP1909788A2 (en) 2005-07-29 2008-04-16 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
EP1944301A4 (en) 2005-10-27 2012-01-04 Msd Kk NEW BENZOXATHIIN DERIVATIVES
US20070197509A1 (en) 2005-12-21 2007-08-23 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
EP1928425B1 (en) 2006-05-12 2013-01-23 Pharmathen S.A. Pharmaceutical formulation containing fluvastatin
WO2008044236A2 (en) * 2006-10-10 2008-04-17 Dexcel Pharma Technologies Ltd. Improved release of statins in the intestine
SI2118074T1 (sl) 2007-02-01 2014-05-30 Resverlogix Corp. Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni
EP2005941A3 (de) 2007-06-01 2009-04-01 Henkel AG & Co. KGaA Zellverjüngende Zusammensetzungen
WO2008152471A1 (en) 2007-06-12 2008-12-18 Coley Pharmaceutical Group, Inc. Quinazoline derivative useful as toll-like receptor antagonist
JP5478262B2 (ja) 2007-12-28 2014-04-23 田辺三菱製薬株式会社 抗癌剤
AU2009262252B2 (en) 2008-06-26 2013-05-02 Resverlogix Corp. Methods of preparing quinazolinone derivatives
CA2732087A1 (en) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Substituted naphthyridines and their use as medicaments
US20100093636A1 (en) 2008-10-06 2010-04-15 Carolus Therapeutics, Inc. Methods of treating inflammation
NZ594332A (en) 2009-01-08 2013-09-27 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular disease
JP2012519661A (ja) 2009-03-06 2012-08-30 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス性複素環化合物
CN105859639A (zh) 2009-03-18 2016-08-17 雷斯韦洛吉克斯公司 新的抗炎剂
BRPI1014956B8 (pt) 2009-04-22 2021-05-25 Resverlogix Corp agentes anti-inflamatórios
NZ807894A (en) * 2009-04-29 2025-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
DE102010048800A1 (de) 2010-10-20 2012-05-10 Merck Patent Gmbh Chinoxalinderivate
GB201018147D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Method of treatment
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
AU2012330885B2 (en) 2011-11-01 2016-10-06 Resverlogix Corp. Oral immediate release formulations for substituted quinazolinones
US20130281397A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US9624244B2 (en) 2012-06-06 2017-04-18 Constellation Pharmaceuticals, Inc. Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
DK2906531T3 (en) 2012-10-15 2018-02-05 Resverlogix Corp APPLICABLE COMPOUNDS IN THE SYNTHESIS OF BENZAMIDE COMPOUNDS
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
CA2895905A1 (en) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Novel heterocyclic compounds as bromodomain inhibitors
AU2014249192B2 (en) 2013-03-11 2017-12-21 The Regents Of The University Of Michigan BET bromodomain inhibitors and therapeutic methods using the same
US9695179B2 (en) 2013-03-14 2017-07-04 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins
TWI530499B (zh) 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
BR112016003584A8 (pt) 2013-08-21 2018-01-30 Resverlogix Corp composições farmaceuticas e uso das mesmas para regressão de placa acelerada
EA201690283A1 (ru) 2013-08-21 2016-07-29 Ресверлоджикс Корп. Композиции и терапевтические способы для ускоренного регресса бляшки

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11015868B2 (en) * 2017-04-25 2021-05-25 Emil Jacob Gulbranson Hay bale dryer
USD940206S1 (en) 2017-04-25 2022-01-04 Emil Jacob Gulbranson Hay bale dryer

Also Published As

Publication number Publication date
ES2745471T3 (es) 2020-03-02
KR20140088893A (ko) 2014-07-11
RU2014115427A (ru) 2015-12-10
CA2851996C (en) 2020-01-07
CN103945848A (zh) 2014-07-23
PL2773354T3 (pl) 2019-12-31
JP2014532638A (ja) 2014-12-08
DK2773354T3 (da) 2019-08-05
US9610251B2 (en) 2017-04-04
US10016426B2 (en) 2018-07-10
RS58911B1 (sr) 2019-08-30
EP2773354A1 (en) 2014-09-10
RU2640115C2 (ru) 2017-12-26
US20130108672A1 (en) 2013-05-02
US20170119767A1 (en) 2017-05-04
PT2773354T (pt) 2019-07-17
HRP20191587T1 (hr) 2019-12-13
TR201909777T4 (tr) 2019-07-22
EP2773354A4 (en) 2015-07-01
CN103945848B (zh) 2016-09-07
AU2012330885B2 (en) 2016-10-06
AU2012330885A1 (en) 2014-04-24
CY1123945T1 (el) 2021-10-29
IL232041A0 (en) 2014-05-28
KR102011641B1 (ko) 2019-08-19
NZ623381A (en) 2016-03-31
LT2773354T (lt) 2019-08-12
HUE044986T2 (hu) 2019-11-28
IN2014CN02751A (enExample) 2015-07-03
WO2013064900A1 (en) 2013-05-10
WO2013064900A8 (en) 2013-07-18
EP2773354B1 (en) 2019-06-12
SI2773354T1 (sl) 2019-08-30
IL232041B (en) 2018-11-29
HK1201751A1 (en) 2015-09-11
CA2851996A1 (en) 2013-05-10

Similar Documents

Publication Publication Date Title
JP5992049B2 (ja) 置換されたキナゾリノンのための経口速放性製剤
JP7058396B2 (ja) 化学療法による心毒性を阻止するための医薬組成物および方法
KR101762999B1 (ko) 종양 치료제
Xie et al. Capsaicin and dihydrocapsaicin induce apoptosis in human glioma cells via ROS and Ca2+‑mediated mitochondrial pathway
WO2015025228A2 (en) Compositions and therapeutic methods for accelerated plaque regression
CA2928028A1 (en) Cromolyn derivatives and related methods of imaging and treatment
CA2921985A1 (en) Compositions and therapeutic methods for accelerated plaque regression
WO2012000421A1 (zh) 棉酚衍生物在制备抗肿瘤药物中的应用
CN103841976A (zh) Akt和mek抑制剂化合物的组合及其使用方法
JP2015214579A (ja) 癌細胞アポトーシス
JP7591283B2 (ja) ブドウ膜黒色腫の治療のための併用療法
TWI867086B (zh) 以rvx-208及sglt2抑制劑治療及/或預防主要不良心血管事件(mace)的方法
AU2013292054B2 (en) Use of VEGFR-3 inhibitors for treating hepatocellular carcinoma
WO2020045461A1 (ja) ピラゾロ［３，４－ｄ］ピリミジン化合物を有効成分とする治療剤
HK1201751B (en) Oral immediate release formulations for substituted quinazolinones
JP2016514125A (ja) バルサルタン及びロスバスタチンカルシウムを含む複合製剤及びその製造方法
US20240252490A1 (en) Combination Therapies Comprising Kras Inhibitors and SPH2 Inhibitors
CN116390721A (zh) 用于用bet溴结构域抑制剂和钠依赖性葡萄糖转运2抑制剂的组合改善肾功能的方法
TW202541800A (zh) 化合物之調配物及其用途
WO2016175092A1 (ja) 肝細胞癌の予防又は治療のための医薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151026

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160802

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160816

R150 Certificate of patent or registration of utility model

Ref document number: 5992049

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250